A Retrospective Multicountry, Multicentric, Cohort Study Analyzing drug survival of Interleukin 17 and IL‑23 Inhibitors in moderate to severe psoriasis patients
Latest Information Update: 24 Aug 2022
At a glance
- Drugs Brodalumab (Primary) ; Guselkumab (Primary) ; Ixekizumab (Primary) ; Risankizumab (Primary) ; Secukinumab (Primary) ; Tildrakizumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
Most Recent Events
- 24 Aug 2022 New trial record
- 17 Aug 2022 Results published in the American Journal of Clinical Dermatology